×

Inc. Magazine Ranks Crescendo Bioscience as the 67th Fastest Growing Private Company in the United States

SOUTH SAN FRANCISCO, Calif., Aug. 22, 2013 (GLOBE NEWSWIRE) -- Inc. magazine has announced that Crescendo Bioscience is the 67th fastest growing private company in the United States, according to its annual listing of private companies, the Inc. 500. Crescendo Bioscience is a molecular diagnostics company dedicated to developing quantitative blood tests and disease information services for rheumatoid arthritis (RA) and other autoimmune diseases. The company's Vectra® DA, a multi-biomarker blood test to assess RA disease activity, was introduced in late 2010 and recently received Medicare coverage.

Each year, Inc. magazine ranks the fastest growing private companies in the United States based on their three year growth rate. Crescendo's 4,740 percent growth rate established it as the 67th fastest growing company in the nation and the 5th out of the top healthcare companies that were included in the list. To be considered for the Inc. 500, companies had to grow more than 918 percent between 2010 and 2012. The average company on the list grew 2,900 percent over that time period.

"We are truly excited to be in the top 100 of the Inc. 500 list. This ranking is a clear result of the vision, spirit, tenacity and ingenuity of the dedicated team we have built here at Crescendo Bioscience," said William H. Hagstrom, President and CEO of Crescendo Bioscience. "Vectra DA fulfills an important unmet need of both rheumatologists and patients in providing an accurate and precise means to quantify a patient's RA disease activity and identify changes in response to treatment."

Vectra DA is the first and only multi-biomarker blood test for rheumatoid arthritis (RA) disease activity and integrates the measurement of 12 serum proteins associated with RA disease activity into a single objective score to help physicians make more informed patient management decisions. Vectra DA has been clinically validated to measure rheumatoid arthritis disease activity in conjunction with standard clinical assessment in adults previously diagnosed with RA.

Vectra DA testing is performed at Crescendo Bioscience's state-of-the-art CLIA (Clinical Laboratory Improvement Amendments) and CAP (College of American Pathology) accredited facility in South San Francisco, CA. Crescendo Bioscience also launched a patient-friendly iOS app called MyRA™, recently named "new and noteworthy" by Apple Magazine. The free app allows RA patients to customize the symptoms they track and to easily report them to physicians to enhance physician-patient communication.

About Inc. and the Inc. 500|5000

Founded in 1979 and acquired in 2005 by Mansueto Ventures, Inc. Magazine is the only major brand dedicated exclusively to owners and managers of growing private companies with the aim to deliver real solutions for today's innovative company builders. Total monthly audience reach for the brand has grown significantly from 2,000,000 in 2010 to over 6,000,000 today. For more information, visit inc.com.

The Inc. 500 is a list of the fastest-growing private companies in the United States. Started in 1982, this prestigious list of the nation's most successful private companies has become the hallmark of entrepreneurial success. Previous recipients have included Microsoft, Intuit, Zappos, Under Armour, Jamba Juice, Timberland, Cliff Bar, Patagonia and Oracle. To view the full 2013 list, go to www.inc.com/inc500.

About Crescendo Bioscience, Inc.

Crescendo Bioscience is a molecular diagnostics company focused in rheumatology and located in South San Francisco, CA. Crescendo Bioscience develops quantitative, objective, blood tests to provide rheumatologists with deeper clinical insights to help enable more effective management of patients with autoimmune and inflammatory diseases. For more information, please visit the company's website at www.CrescendoBio.com.

CONTACT: Media Contact: Terri Clevenger Continuum Health Communications (203) 856-4326 tclevenger@continuumhealthcom.comSource: Crescendo Bioscience